CD274 and neoplasm: In their study, Li et al. found that a dual-targeted approach was required in order to effectively combat tumour reoccurrence, combining TSA with anti-PD-L1 therapy to significantly enhance tumour reduction durability and prolong survival of tumour-bearing mice [268].